Olav Hellebø takes the helm at ReNeuron; Mylan buys drug rights in $300M deal;

@FierceBiotech: FDA panel spurns $ACT's cardio combo, jeopardizing its potential. Story | Follow @FierceBiotech

@JohnCFierce: Xenon pitches Genentech, Teva "extreme genetics" ties as it rolls out a $52M. News | Follow @JohnCFierce

@DamianFierce: $AGN and Ackman have resorted to WWE-level taunts and provocations and it hasn't stopped being entertaining. Article via Reuters | Follow @DamianFierce

@EmilyMFierce: Compound inhibits both MERS, SARS. More | Follow @EmilyMFierce

> Biotech vet Olav Hellebø has taken the reins at ReNeuron, a regenerative medicines company that is slated to relocate to Wales next year. Hellebø had led Norway's Clavis, which experienced a couple of key setbacks in an attempt to develop new cancer therapies. Sir Chris Evans, the high-flying UK biotech entrepreneur, is one of the key players backing ReNeuron. Story

> Mylan ($MYL) grabbed the U.S. commercialization, marketing and intellectual property rights relating to Arixtra (fondaparinux sodium) Injection from Aspen Global in a $300 million deal. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Study: Fecal incontinence implants reduce weekly incontinence episodes in women. Article | Follow @FierceMedDev

@VarunSaxena2: Novel epitope for binding of HIV antibodies has major drug delivery implications. FierceDrugDelivery story | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. Report | Follow @MichaelGFierce

@EmilyWFierce: Physicians find little difference between old and new orthopedic implants, suggest "facts box" for knee & hip devices. MedPage Today article | Follow @EmilyWFierce

> Scientist who discovered BRCA breast cancer gene advocates for systematic screening. More

> Study shows COPD device effective in deterring mucus buildup. Story

Pharma News

@FiercePharma: Top-read in FiercePharmaManufacturing Tues: Perrigo recalls 367,000 tubes of nicotine lozenges. Story | Follow @FiercePharma

@EricPFierce: Cipla is spending $17M to buy two plants from one of its contractors. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI, Our latest special report - The top 10 best-selling MS drugs of 2013 - is here. Report | Follow @CarlyHFierce

> With $1M gene therapies coming, research pioneer and CVS plot new payment route. More

> Wake up, Ackman tells Allergan's board. He has a 50%-60% chance of replacing you. Story

Drug Delivery News

> Microneedle patch delivers painkiller to second layer of skin in 5 minutes. Report

> Low T products under FDA scrutiny over safety concerns. Item

> Novaliq dissolvable drops improve eye quality in clinical trials. Story

> HIV-fighting intravaginal ring research nets $20M from NIH. More

> Novel epitope for binding of HIV antibodies has major drug delivery implications. Article

Diagnostics News

> Veracyte grabs Allegro Diagnostics for $21M and jumps into lung cancer test space. News

> U.K. test may help Roche's cancer drug Avastin target ideal patients. More

> GE Healthcare, FBI allege Chinese engineer stole MRI trade secrets. Report

> ASCO: Provista's autoantibody/biomarker combo boosts breast cancer screening accuracy. Article

> Myriad's multigene predictive cancer test shows utility in new trial. Story

Pharma Marketing News

> Attention market-access experts: NICE won't take pharma's word on cost-effectiveness anymore. Item

> Think a $150K cancer drug is pricey? Try a $1M-plus gene therapy. Editor's corner

> Teva goes analog for asthma with hands-on waiting-room game. Article

> Auxilium's Low-T woes put sales reps in line for layoffs. Story

> Free speech, PhRMA? Not in this off-label marketing case, feds say. More

Suggested Articles

The VC shop raised the money across two funds that will deploy cash to help biotechs get started and grow into more established players.

Nearly two years after raising $75 million, iTeos Therapeutics is picking up $125 million to push its lead assets through phase 1/2 trials.

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.